Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
about
Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adultsAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateProgress of molecular targeted therapies for prostate cancersHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerA systems biology view of blood vessel growth and remodellingSTAT5a/b contribute to sex bias in vascular disease: A neuroendocrine perspectiveProposal of a hybrid approach for tumor progression and tumor-induced angiogenesisPDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancerSynthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growthAntiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenograftsMRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.Combinatory action of VEGFR2 and MAP kinase pathways maintains endothelial-cell integrity.Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming.Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies.Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts.Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinomaVascular endothelial growth factor receptor 1 contributes to Escherichia coli K1 invasion of human brain microvascular endothelial cells through the phosphatidylinositol 3-kinase/Akt signaling pathway.Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells.Corneal neovascularization: an anti-VEGF therapy review.Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer.Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction.A method to assess target gene involvement in angiogenesis in vitro and in vivo using lentiviral vectors expressing shRNAHuman urothelial carcinoma cell response to Sunitinib malate therapy in vitro.Tumor lymphangiogenesis as a potential therapeutic target.Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?SRC points the way to biomarkers and chemotherapeutic targets.Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy
P2860
Q24187730-D8B3D59E-CBEC-4C79-934C-AE6A6B6F5041Q24608039-0E5EF4F3-BF68-4D3E-8356-A988001A525AQ26822717-1FF6078A-9BBA-427D-B1E7-7B7B9282C4DCQ26823014-2C382577-3CB5-4EB9-956A-497B82A5EF51Q26863418-86C210D5-60A5-4935-88CF-6029C2B1AD61Q27003945-FDA6E568-4FF7-4C78-8DAF-9F3F450F84DFQ28081115-713CFA41-9C05-48F9-AD9E-2F0726DB6520Q28084050-A70FB7CF-52B0-4B59-AA48-128EA8C65511Q28085644-C9E5CF4A-12E0-4085-84A0-32E8361EF2CDQ28538093-F010A9B5-111B-4CE4-9D0A-AC6F81062A74Q30855619-0071D858-DF23-4716-9016-E0A59C54F758Q33616649-EA9FF99A-BA56-42B2-BE4F-89C5B79F2C0AQ33624207-0E5F94F1-5508-4A74-BC9C-AF2B89D7C7D9Q33851194-8919EF18-4EE8-4CF1-9E84-F7B11C7F86A7Q34052411-BE091E90-D7AA-4C69-B24B-CDB256F71146Q34124396-181D3911-1399-431B-AE5C-FAFD33C27C2FQ34193426-11D64DE2-5970-44E0-AA39-0B4520CA30E3Q34246117-1D409851-F699-4F83-811A-EA28E24EDDBBQ34249349-02AFA322-31F5-4823-9A0F-955F8A891AF5Q34282488-72D91F41-BAB5-4031-BFEB-7F236A207232Q34290785-88C674C1-4A82-4787-B2D5-B566B3620924Q34371248-D0CF2FA5-7F5C-4AE4-A1B5-D5CCCA86CBCFQ34402998-27581D8A-EFEC-462B-931E-18EE5C7093FAQ34460026-7F186247-3F96-4108-9872-B34917264E63Q34567910-5B85739C-DB77-4D52-8D21-DF8E980202AEQ34641522-FF4C00B0-9BD2-499D-82A9-150BB2874EAFQ34937019-91543C94-CCE3-4BEA-B2AC-21E1C361EBEAQ35001062-4DC1FB03-5C1B-44B4-BADC-48CDF32EC88EQ35028389-EA6CB14D-153A-4AB1-AAE5-FD8EF138EDE3Q35039240-A34178B0-AFEA-4F01-8A09-3D86DAA9FA5BQ35083762-315B5278-D0EE-4F0E-9F5D-C9B3D3EEB1DEQ35156024-E58565C7-AF67-471E-9361-EEF389D3D777Q35572636-733588AF-84B7-47A6-8437-D679DED9D0D6Q35838122-9E66EAFD-2225-4116-9116-74B99BD41894Q35843084-28F261C0-FF82-4A81-A768-6BB68B54BAA9Q36084341-140FD577-88EB-4A6E-BD2C-2C3A7505DF4FQ36186882-DA268FAB-CC66-4065-87CC-247B8DAC8AE2Q36288817-3B5B1E26-1B2C-40F5-80AA-C99DF4360B04Q36443406-303D6B22-150F-4A16-9DD6-0D1AEC8F48E1Q36483105-A4CB0988-BEF3-472D-AF92-7BDA62F5B5B6
P2860
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@ast
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@en
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@nl
type
label
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@ast
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@en
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@nl
prefLabel
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@ast
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@en
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@nl
P1476
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
@en
P304
P356
10.1016/J.BBRC.2007.02.156
P407
P577
2007-03-07T00:00:00Z